IBD Therapeutics - Ward

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/56

encourage image

There's no tags or description

Looks like no tags are added yet.

57 Terms

1
New cards

Parts of IBD disease burden

Inflammatory activity

Disability

Symptoms + Quality of life

Psychological health

Hospitalizations and surgery

2
New cards

Assessing disease severity

Inflammatory burden - mucosal lesions, biomarkers

Diseases impact on patients - quality of life, symptoms

Complicated Disease course - recurrent flares, intestinal damage, disease phenotype

Impact of patient on disease - coping strategies, healthcare utilization, shared decision making, treatment adherence

3
New cards

Disease phenotype

Displayed traits like age, location, and behavior

4
New cards

Goals of IBD Therapy

Symptomatology/Response

Remission

Mucosal healing

Quality of life

Alter disease course

5
New cards

Short term goals of IBD treatment

Symptom improvement (HBI, CDAI, SCCAI)

Biochemical response/remission

Quality of life and psychological health

6
New cards

When to reassess short term goals

6-12 weeks

7
New cards

Intermediate goals of Therapy for IBD

Symptom remission

Mucosal healing

Quality of life and psychological health

8
New cards

When to reassess intermediate goals

every 6-12 months

9
New cards

Long term goals of therapy for IBD

Reduce disability

Reduce dysplasia

Alter natural history of disease

10
New cards

When to reassess long term goals

1-5 years

11
New cards

Treat to target IBD

Set a predefined therapeutic goal and monitor it

12
New cards

Short Term Target

Clinical Response

>50% decrease in PRO2

13
New cards

Intermediate Target

Clinical remission and biomarker normalization

14
New cards

Additional long-term target

Restore QoL, decrease disability

15
New cards

Long term target

Endoscopic healing

16
New cards

Malabsorption/nutritional support NonPharm

Enteral nutrition is effective, some patients may need tube feeding

Parenteral nutrition is reserved for complicated disease or patients who tried parenteral and are not gaining weight

Screen for micronutrient deficiencies

17
New cards

Probiotics Nonpharm

Help support normal GI microbiome but can be expensive and hard to time dosing

18
New cards

Exacerbating factors of IBS

Smoking, Infections, NSAID use, stress

19
New cards

Surgery for IBD

Potentially curative for UC

High recurrence rates for CD

Usually need to get an ostomy while healing

20
New cards

T2T Goals

Resolution of acute disease symptoms

Induction and maintenance of remission

21
New cards

What determines IBD treatment (dose, route, frequency)

Severity

Extent

Location

Disease Complications

22
New cards

Pharmacologic Therapy for mild to moderate disease

Amino salicylates

Corticosteroids

Antimicrobials

23
New cards

Pharmacologic therapy for moderate-severe or fulminant diseases

Immunomodulators

mAbs and TNF-a antibodies

24
New cards

Kinds of aminosalicylates

Sulfasalazine

Mesalamine

Balsalazide

Olsalazine

All contraindicated in a salicylate allergy

25
New cards

Sulfasalazine (Azulfidine)

Combination of sulfonamide antibiotic (sulfapyridine) and mesalamine. Less expensive. Contraindicated with sulfa allergy.

26
New cards

Sulfasalazine AEs

Are dose dependent (>4 grams)

N/V, anorexia, alopecia, GI distress, HA, oligospermia, pancreatitis, blood dyscrasias, interstitial nephritis

27
New cards

Blood dyscrasiasis

agranulocytosis, aplastic anemia

Not producing enough neutrophils + bone marrow is not producing any blood cells

28
New cards

Managing Sulfasalazine AEs

For acute intolerance - discontinue or restart at lower dose and titrate uo

Give with food

Co prescribe folic acid 1mg/day to prevent anemia

Use mesalamine alone

29
New cards

Mesalamine PK

Design drugs to deliver mesalamine to affected areas w/o premature absorption

Completely absorbed in small intestine

Poorly absorbed in colon, but exerts local effect

30
New cards

Mesalamine

Better tolerated than sulfasalazine

31
New cards

AEs of mesalamine

Nausea, dyspepsia, abdominal cramping, diarrhea, HA, pancreatitis, arthralgia, cutaneous reactions

32
New cards

Types of UC + dosage form

Ulcerative Proctitis - suppository

Left-sided colitis -suppository + enema

Pancolitis - PO

33
New cards

Pentasa

Works in duodenum-rectum

Diffusion dependent

34
New cards

Delzicol, Apriso

pH-dependent, enteric coating, enteric coating + polymer matrix

Proximal colon - rectum

35
New cards

Asacol

pH-dependent, enteric coating

Terminal ileum - rectum

36
New cards

Lialda

pH + MMX + enteric coating

Proximal colon - rectum

37
New cards

Balsalazide

Mesalamine prodrug

Uses an inert carrier molecule to transport mesalamine to the colon

Undergoes enzymatic cleavage to release mesalamine

38
New cards

Olsalazine

Bacteria cleave olsalazine, releasing mesalamine.

Dose dependent diarrhea, 15-35% incidence

39
New cards

Corticosteroids

Suppress acute inflammation

Modulate the immune system and inhibit cytokine and inflammatory mediators

May be given orally, rectally, parenterally in moderate-severe or fulminant disease

40
New cards

Budesonide (Uceris, Entocort EC)

Oral, controlled release

Releases in the terminal ileum or colon

Low systemic bioavailability due to 1st pass metabolism, less AEs

May minimize adrenal suppression compared to other steroid options

Also available in rectal foam for distal disease

41
New cards

Prednisone

Oral

Requires tapering if used long-term

Increased risk of osteoporosis - consider vit D and calcium supplements

(1000-1200 calcium, 600-800 units D)

DEXA scan

42
New cards

Antimicrobial agents for IBD

Limited role as adjunctive therapy. Use metronidazole. Usually used for perianal fistulas

43
New cards

Perianal Fistulas

Communicates with exterior or another body cavity

Often formed from an abscess that can’t heal

44
New cards

Risks of long term metronidazole use

C. diff

Antibiotic resistance

Neurotoxicity

45
New cards
46
New cards

Induction mild-moderate proctitis regimen

5-ASA supp 1g/day

or

5-ASA enema >/= 1g/day

47
New cards

Induction left sided colitis regimen

5-ASA enema >/= 1g/day + PO 5-ASA >/= 2g/day

48
New cards

Induction Extensive/Pancolitis regimen

5-ASA PO >/= 2g/day

Budesonide MMX 9mg/day

49
New cards

UC not responding to PO 5-ASA

Use oral budesonide MMX 9mg/day to induce remission

50
New cards

Goals of CD treatment

Induce remission

Mucosal healing

Improve quality of life/mental health

51
New cards

Why is CD more difficult to treat than UC

Complexity of presentation

Aggressive nature of the disease

Greater reliance on drugs, surgery more difficult

52
New cards

Poor prognostic factors of CD

Young age at time of diagnosis

Ileal/ileocolonic involvement

Initial extensive bowel involvement

Perianal/severe rectal disease

Deep ulcers

Penetrating or stricturing phenotype at diagnosis

Extraintestinal manifestations at diagnosis

53
New cards

Induction of mild colonic or ileocolonic CD

Sulfasalazine 3-6g/day divided into 3-6 doses

54
New cards

Induction of mild-moderate ileocecal CD

Budesonide PO 9mg/day for controlled ileal release

55
New cards

Is oral mesalamine recommended for CD

No

56
New cards

What treatments are discouraged for CD maintenance

PO mesalamine

PO budesonide

57
New cards

Is there any agent endorsed for maintenance of CD

No, generally need immunologic therapy